http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Corbus Pharmaceuticals Presents Additional Data from RESOLVE-1 Study in Systemic Sclerosis
-
Corbus Pharmaceuticals to Report Third Quarter Results on November 10, 2020
-
Corbus Pharmaceuticals to Report Third Quarter Results on November 10, 2020
-
Corbus Pharmaceuticals Announces Presentation of Data from its Phase 2b Study in Cystic Fibrosis at NACFC 2020
-
Corbus Pharmaceuticals Announces Presentation of Data from its Phase 2b Study in Cystic Fibrosis at NACFC 2020
-
Corbus Pharmaceuticals (CRBP) Announces Three Lenabasum Abstracts to be Presented at ACR Convergence 2020
-
Corbus Pharmaceuticals Announces Three Lenabasum Abstracts to be Presented at ACR Convergence 2020
-
Corbus Pharmaceuticals Announces Three Lenabasum Abstracts to be Presented at ACR Convergence 2020
-
Corbus Pharma (CRBP) Announces Corporate Restructuring and Pipeline Portfolio Updates
-
Corbus Pharmaceuticals Announces Corporate Restructuring and Pipeline Portfolio Updates
-
Corbus Pharmaceuticals Announces Corporate Restructuring and Pipeline Portfolio Updates
-
Corbus Pharma (CRBP) Announces Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis Did Not Meet Primary Endpoint
-
Corbus Pharmaceuticals Announces Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis Did Not Meet Primary Endpoint
-
Corbus Pharmaceuticals Announces Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis Did Not Meet Primary Endpoint
-
Corbus Pharma (CRBP) Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis Showed No Significant Differences in Primary and Secondary Endpoints
-
Corbus Pharmaceuticals Announces Topline Results from RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis
-
Corbus Pharmaceuticals Announces Topline Results from RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis
-
Corbus Pharmaceuticals Reports Second Quarter Financial Results and Corporate Updates
-
Corbus Pharmaceuticals Reports Second Quarter Financial Results and Corporate Updates
-
Corbus Pharma (CRBP) Reports Complete Enrollment in DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis
-
Corbus Pharmaceuticals Completes Enrollment in DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis
-
Corbus Pharmaceuticals Completes Enrollment in DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis
-
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences
-
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences
-
Corbus Pharmaceuticals to Report Second Quarter Results on August 6, 2020
-
Corbus Pharmaceuticals to Report Second Quarter Results on August 6, 2020
-
Corbus Pharma (CRBP) received $71 million in gross proceeds from its at-the-market offering coupled with execution of $50 million debt financing facility
-
Corbus Pharmaceuticals Strengthens Balance Sheet with up to $121 Million in New Capital
-
Corbus Pharmaceuticals Strengthens Balance Sheet with up to $121 Million in New Capital
-
Corbus Pharma (CRBP) Names George Golumbeski, Ph.D. to Board
-
Corbus Pharmaceuticals Appoints George Golumbeski, Ph.D., to Board of Directors
-
Corbus Pharmaceuticals Appoints George Golumbeski, Ph.D., to Board of Directors
-
Corbus Pharmaceuticals Presents Data Demonstrating ACR CRISS Score Reflects Patient-Reported Outcomes at 6th Systemic Sclerosis World E-Congress
-
Corbus Pharmaceuticals Presents Data Demonstrating ACR CRISS Score Reflects Patient-Reported Outcomes at 6th Systemic Sclerosis World E-Congress
-
Corbus Pharma (CRBP) Announces Last Subject Visit in Phase 2b Study of Lenabasum for Treatment of CF
-
Corbus Pharmaceuticals Reports Last Subject Visit in Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis
-
Corbus Pharmaceuticals Reports Last Subject Visit in Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis
-
Corbus Pharma (CRBP) Reports Publication of Phase 2b Cystic Fibrosis Study Patient Demographics & Baseline Disease Characteristics
-
Corbus Pharmaceuticals Announces Publication of Phase 2b Cystic Fibrosis Study Patient Demographics and Baseline Disease Characteristics in the Journal of Cystic Fibrosis
-
Corbus Pharmaceuticals Announces Publication of Phase 2b Cystic Fibrosis Study Patient Demographics and Baseline Disease Characteristics in the Journal of Cystic Fibrosis
-
Corbus Pharma (CRBP) Announces Last Subject Visit in RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis
-
Corbus Pharmaceuticals Reports Last Subject Visit in RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis
-
Corbus Pharmaceuticals Reports Last Subject Visit in RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis
-
Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2020 E-Congress
-
Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2020 E-Congress
-
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences
-
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences
-
Corbus Pharmaceuticals Reports First Quarter Financial Results and Corporate Updates
-
Corbus Pharmaceuticals Reports First Quarter Financial Results and Corporate Updates
-
Corbus Pharmaceuticals to Report First Quarter Results on May 11, 2020
